For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 5,254,966 | 2,424,346* | 925,377 | 1,298,041 |
| General and administrative | 11,416,586 | 3,350,878.5* | 1,918,971 | 2,076,108 |
| Total expenses | 16,671,552 | 5,775,224.5 | 2,844,348 | 3,374,149 |
| Loss from operations | -16,671,552 | -5,775,224.5* | -2,844,348 | -3,374,149 |
| Foreign exchange losses | -1,804 | -15,521* | -6,246 | -21,110 |
| Investment income | 629,602 | 583,155.5* | 106,640 | 136,671 |
| Loss on issuance of convertible preferred stock and warrants | - | 289,783,590.75* | - | - |
| Warrant issuance cost | - | 775,662.25* | - | - |
| Changes in fair value of the warrant liability | 109,360,630 | -11,347,479* | - | - |
| Net loss | -125,404,384 | -284,419,364 | -2,743,954 | -3,258,588 |
| Basic EPS | -2.86 | -27.741 | -0.36 | -0.43 |
| Diluted EPS | -2.86 | -27.741 | -0.36 | -0.43 |
| Basic Average Shares | 43,900,426 | 10,252,781 | 7,568,981 | 7,568,981 |
| Diluted Average Shares | 43,900,426 | 10,252,781 | 7,568,981 | 7,568,981 |
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)